Clinical diagnosis and management of pancreatic mucinous cystadenoma and cystadenocarcinoma: Single-center experience with 82 patients

Table 1 Patient characteristics in the two treatment groups, n (%)

Patient characteristic	MCA (n = 70)	MCC (n = 12)	P value
Age, yr, mean ± SD	46.2 ± 13.1	56.8 ± 9.4	0.0081
Sex (male:female)	5:65	2:10	0.271
Location, distal pancreas	54 (77.1)	7 (58.3)	0.280
Tumor size, cm, median (IQR)	3.5 (2.5-6.1)	5.8 (4.0-6.9)	0.0491
CEA (µg/L), median (IQR)	1.4 (1.0-2.2)	2.7 (1.6-5.5)	0.0051
> 5 µg/L	2	3	0.0211
CA19-9 (U/mL), median (IQR)	14.2 (8.5-29.1)	39.9 (13.0-71.0)	0.0261
> 37 U/mL	13	6	0.0271
CA12-5 (U/mL), median (IQR)	12.1 (7.7-19.4)	19.0 (10.8-36)	0.0371
> 35 U/mL	3	3	0.0381
Operative, minimally invasive	66 (94.3)	8 (66.7)	0.0141

¹Values are statistically significant. MCA: Mucinous cystadenoma; MCC: Mucinous cystadenocarcinomas; IQR: Interquartile range; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA12-5: Carbohydrate antigen 12-5.